local
interfer
cytokin
signal
mediat
sirnaload
nanoparticl
might
promis
new
therapeut
approach
dampen
inflamm
pulmonari
diseas
local
therapeut
treatment
pulmonari
inflamm
produc
multishel
nanoparticl
consist
calcium
phosphat
core
coat
sirna
direct
proinflammatori
mediat
encapsul
poli
lacticcoglycol
acid
coat
final
outer
layer
polyethylenimin
nasal
instil
nanoparticl
load
mixtur
sirna
direct
differ
cytokin
mice
suffer
h
cellmedi
lung
inflamm
sirna
direct
influenza
infect
model
led
signific
reduct
target
gene
express
accompani
distinct
amelior
lung
inflamm
model
thu
studi
provid
strong
evid
specif
local
modul
inflammatori
respons
capplga
nanoparticlemedi
sirna
deliveri
could
promis
approach
treatment
inflammatori
disord
lung
pulmonari
inflammatori
diseas
chronic
obstruct
pulmonari
diseas
copd
interstiti
lung
diseas
ild
high
preval
around
world
character
mostli
chronic
inflamm
irrevers
airway
destruct
addit
clinic
symptom
includ
cough
dyspnea
system
effect
report
main
caus
death
patient
suffer
copd
etiolog
diseas
fulli
understood
environment
factor
inhal
air
pollut
genet
suscept
contribut
pathogenesi
inhal
irrit
follow
activ
alveolar
macrophag
lead
secret
chemokin
cytokin
therebi
continu
influx
immun
cell
lung
result
inflammatori
respons
airway
despit
ongo
research
avail
therapi
aim
minim
symptom
date
therapi
interfer
underli
mechan
inflamm
reach
clinic
admiss
recent
advanc
use
biolog
treatment
inflammatori
condit
led
new
approach
therapi
chronic
pulmonari
inflamm
alter
cytokin
chemokin
profil
found
patient
chronic
pulmonari
inflamm
therapi
aim
neutral
cytokin
block
chemokin
receptor
regard
promis
approach
sever
medic
develop
reach
clinic
trial
far
trial
reach
clinic
signific
suggest
drug
affect
synthesi
sever
cytokin
may
success
medic
target
one
specif
cytokin
receptor
one
new
way
interfer
cytokin
signal
use
gene
silenc
rna
interfer
rna
interfer
mediat
small
interf
rna
sirna
base
pair
natur
occur
mechan
posttranscript
gene
silenc
main
limit
rna
interfer
therapeut
purpos
success
local
deliveri
target
cell
transport
cytoplasm
difficult
due
instabl
suscept
degrad
nucleas
among
deliveri
vehicl
calcium
phosphat
cap
nanoparticl
shown
highli
effici
carrier
small
molecul
cell
miner
human
hard
tissu
like
teeth
bone
calcium
phosphat
biocompat
degrad
compound
previou
studi
cappoli
lacticcoglycol
acid
plga
nanoparticl
design
success
therapeut
deliveri
sirna
gut
follow
promis
result
sirna
deliveri
investig
potenti
biodegrad
nontox
sirnaload
capplga
nanoparticl
therapeut
interfer
pulmonari
inflamm
analyz
uptak
nanoparticl
cell
present
lung
vivo
examin
therapeut
effici
sirnaload
capplga
nanoparticl
mice
suffer
h
cell
induc
lung
inflamm
viral
infect
nasal
instil
nanoparticl
prepar
function
describ
previous
brief
singl
shell
capsirna
nanoparticl
synthes
mix
equal
amount
aqueou
solut
calciumllact
mm
diammonium
hydrogen
phosphat
mm
mix
calcium
phosphat
dispers
mix
solut
either
function
sirna
scrambl
sirna
ge
healthcar
life
scienc
chalfont
st
gile
uk
fluorescencelabel
oligonucleotid
life
technolog
darmstadt
germani
mg
ml
encapsul
calcium
phosphat
nanoparticl
biodegrad
polym
poli
llactidecoglycolid
plga
rg
h
evonik
industri
darmstadt
germani
waterinoilinwat
doubl
emuls
solvent
evapor
method
appli
dispers
polyvinylalcohol
pva
coat
nanoparticl
purifi
centrifug
shockfrozen
liquid
nitrogen
lyophil
freezedri
particl
resuspend
solut
aqueou
pei
mg
ml
branch
sigmaaldrich
st
loui
missouri
usa
ratio
ww
obtain
final
nanoparticl
structur
particl
character
scan
electron
microscopi
esem
quanta
sputter
goldpalladium
dynam
light
scatter
perform
zetas
nanoseri
instrument
nanoz
malvern
laser
wavelength
nm
balbc
mice
purchas
harlan
laboratori
harlan
winkelmann
gmbh
borchen
germani
spcha
mice
express
influenza
ha
control
specif
alveolar
epitheli
cell
promot
surfact
protein
c
tcrha
transgen
mice
exhibit
cell
express
specif
mhc
class
ii
ha
restrict
epitop
ha
protein
anim
use
studi
hous
specif
pathogenfre
condit
laboratori
anim
facil
univers
hospit
essen
experi
perform
accord
state
feder
guidelin
approv
north
rhinewestphalia
state
agenc
natur
environ
consum
protect
germani
singl
cell
suspens
lung
liver
obtain
digest
media
contain
fc
uml
collagenas
iv
clostridium
histolyticum
sigmaaldrich
bonn
germani
collagenas
roch
mannheim
germani
respect
minut
sampl
pipet
everi
minut
afterward
remain
tissu
squash
cell
strainer
wash
pb
contain
fc
mm
edta
erythrocyt
lysi
buffer
respect
spleen
lymph
node
squash
cell
strainer
wash
erythrocyt
lysi
buffer
pb
contain
fc
mm
edta
respect
cell
enrich
spleen
tcrha
transgen
mice
use
automac
technolog
miltenyi
biotech
bergischgladbach
germani
accord
manufactur
instruct
haspecif
cell
obtain
stain
cell
antibodi
haspecif
tcr
sort
flow
cytometri
use
aria
ii
sorter
bd
bioscienc
heidelberg
germani
haspecif
cell
sort
activ
vitro
platebound
solubl
antibodi
bd
bioscienc
polar
produc
h
cell
ad
recombin
mous
r
system
wiesbaden
germani
antibodi
ebiosci
san
diego
ca
media
day
h
polar
confirm
flow
cytometr
stain
induct
inflamm
spcha
transgen
mice
treatment
nanoparticl
haspecif
h
cell
adopt
transfer
spcha
transgen
mice
nontransgen
litterm
mice
monitor
daili
sign
sick
sacrif
day
transfer
analysi
treatment
nanoparticl
mice
anesthet
ketaminexylazin
sirnaload
capplga
nanoparticl
suspens
contain
sirna
administ
nasal
instil
use
pipett
mice
sacrif
ripcag
remov
trachea
expos
cathet
insert
care
lower
trachea
pb
slowli
infus
lung
via
cathet
fluid
taken
procedur
repeat
three
time
fluid
collect
later
luminex
assay
analysi
flow
cytometr
analysi
perform
canto
ii
flow
cytomet
use
fac
diva
softwar
bd
bioscienc
oligonucleotid
label
life
technolog
dead
cell
exclud
stain
cell
ebiosci
san
diego
california
usa
fixabl
viabil
dye
ebiosci
analysi
perform
use
antibodi
mhcii
biolegend
san
diego
ca
ebiosci
san
diego
ca
bd
bioscienc
heidelberg
germani
conjug
fluorescein
isothiocyan
phyocerythrin
pacif
blue
brilliant
violet
uptak
analysi
lung
cell
divid
dc
mhcii
macrophag
med
alveolar
macrophag
hi
med
high
auto
fluoresc
epitheli
cell
neg
alveolar
epitheli
cell
type
epitheli
cell
alveolar
epitheli
cell
type
ii
epitheli
cell
high
side
scatter
sedat
mice
receiv
singl
intranas
inject
capplga
nanoparticl
sirna
correspond
mg
nanoparticl
prior
imag
use
pipett
uptak
lung
examin
use
vivo
imag
system
calip
lumina
ii
calip
life
scienc
hopkinton
massachusett
usa
imag
analyz
use
live
imag
softwar
lung
fix
buffer
formalin
embed
paraffin
section
thick
stain
hematoxylin
eosin
total
histolog
score
compos
paramet
inflamm
type
iipneumocyt
hyperplasia
alveolar
histiocytosi
infiltr
neutrophil
student
test
oneway
anova
follow
tukey
multipl
comparison
test
use
determin
statist
signific
set
level
p
b
capplga
nanoparticl
prepar
multistep
process
describ
previous
cap
core
coat
sirna
fluorescencelabel
oligonucleotid
encapsul
plga
final
coat
polyethylenimin
pei
composit
previous
found
group
especi
potent
success
deliveri
releas
nucleic
acid
cell
mucos
surfac
success
synthesi
evalu
scan
electron
microscopi
figur
dynam
light
scatter
measur
figur
b
final
nanoparticl
homogen
spheric
morpholog
exhibit
averag
diamet
nm
zetapotenti
mv
figur
c
confirm
colloid
stabil
water
address
sirnaload
capplga
nanoparticl
use
local
deliveri
vehicl
pulmonari
diseas
vivo
deliveri
nanoparticl
lung
nasal
instil
evalu
fluorescencelabel
capplga
nanoparticl
administ
balbc
mice
hour
postadministr
fluoresc
signal
detect
lung
mice
treat
nanoparticl
demonstr
vivo
life
imag
figur
well
fluoresc
microscopi
tissu
section
figur
b
furthermor
variabl
uptak
nanoparticl
differ
anim
low
indic
compar
reproduc
uptak
experiment
set
figur
analyz
gener
distribut
uptak
nanoparticl
analyz
one
hour
nasal
instil
differ
organ
flow
cytometri
major
part
cap
plga
nanoparticl
remain
lung
weak
signal
addit
detect
bronchial
lymph
node
bln
almost
signal
measur
spleen
liver
mesenter
lymph
node
figur
c
indic
local
rather
system
distribut
flow
cytometr
analysi
lung
demonstr
macrophag
dendrit
cell
main
cell
popul
intern
function
cap
plga
nanoparticl
epitheli
cell
lymphocyt
endocytos
nanoparticl
figur
c
result
confirm
local
uptak
function
capplga
nanoparticl
lung
vivo
nasal
instil
diminish
possibl
side
effect
analyz
therapeut
approach
use
sirnaload
capplga
nanoparticl
determin
potenti
target
gene
h
model
pulmonari
inflamm
use
cell
receptor
tcr
transgen
haspecif
cell
tcrha
transgen
mice
sort
differenti
h
cell
vitro
differenti
effici
determin
day
analysi
product
figur
approxim
cell
produc
confirm
h
phenotyp
differenti
haspecif
h
cell
transfer
spcha
transgen
mice
express
influenza
ha
control
specif
alveolar
epitheli
cell
promot
surfact
protein
c
mice
monitor
daili
sign
sick
measur
bodi
weight
compar
nontransgen
litterm
transgen
mice
start
lose
weight
day
onward
reach
weight
day
figur
b
day
lung
analyz
histopatholog
reveal
inflamm
transgen
mice
destruct
lung
structur
compar
nontransgen
mice
exhibit
patholog
alter
figur
c
cytokin
chemokin
signal
play
import
role
pulmonari
infect
inflamm
instanc
copd
sever
cytokin
report
elev
fluid
obtain
bronchoalveolar
lavag
biopsi
lung
determin
target
gene
sirna
treatment
diseas
model
biopsi
lung
analyz
express
sever
cytokin
diseas
spcha
transgen
mice
express
significantli
increas
level
kc
compar
healthi
litterm
transfer
h
cell
figur
elev
express
confirm
protein
level
fluid
obtain
bronchoalveolar
lavag
figur
e
strongest
increas
compar
nontransgen
mice
detect
express
mrna
protein
level
also
kc
significantli
elev
mice
suffer
h
pulmonari
inflamm
promin
express
mrna
level
found
therefor
gene
chosen
therapeut
target
diseas
model
examin
therapeut
potenti
sirnaload
cap
plga
nanoparticl
spcha
mice
treat
mixtur
sirna
scrambl
sirnaload
nanoparticl
day
h
cell
transfer
figur
treatment
weight
loss
monitor
daili
nontransgen
mice
lose
weight
cell
transfer
spcha
transgen
mice
treat
scrambl
sirnaload
nanoparticl
pb
exhibit
weight
loss
day
interestingli
transgen
mice
treat
specif
sirna
lost
less
weight
anim
control
group
figur
b
mice
sacrif
day
analyz
importantli
mice
treat
sirnaload
capplga
nanoparticl
significantli
reduc
number
cell
within
bal
fluid
compar
scrambl
control
pb
treat
mice
indic
less
sever
inflamm
patient
suffer
pulmonari
inflamm
often
exhibit
influx
immun
cell
due
increas
chemokin
product
figur
c
furthermor
lung
tissu
mice
treat
sirna
less
sever
inflam
tissu
control
anim
less
alveolar
epitheli
cell
type
ii
hyperplasia
reduc
accumul
alveolar
macrophag
decreas
number
neutrophil
interstitium
found
sirnatr
mice
also
reflect
significantli
reduc
histolog
score
lung
tissu
figur
final
valid
potenti
benefici
effect
sirnaload
capplga
nanoparticl
treatment
due
decreas
express
target
gene
biopsi
lung
fluid
bal
analyz
gene
express
inde
express
three
target
gene
significantli
decreas
mrna
protein
level
figur
e
express
reduc
compar
scrambl
control
treat
anim
mrna
protein
level
express
lung
tissu
decreas
mrna
level
downregul
protein
level
less
promin
nevertheless
reduc
product
also
significantli
diminish
protein
level
summari
result
indic
benefici
therapeut
effect
sirnaload
capplga
nanoparticl
inflamm
lung
addit
inflammatori
diseas
lung
prone
viral
infect
viral
infect
vaccin
avail
diseas
like
sever
acut
respiratori
syndrom
caus
coronaviru
curabl
vaccin
exist
therapeut
rather
prophylact
approach
treat
viral
infect
use
sirna
interfer
reproduct
viru
inhibit
spread
verifi
interfer
possibl
reduc
viral
load
capplga
nanoparticl
load
sirna
direct
nonstructur
protein
influenza
viru
balbc
mice
infect
influenza
viru
treat
sirnaload
nanoparticl
two
day
post
infect
analyz
sign
sick
day
figur
verifi
viral
protein
express
alter
due
treatment
sirnaload
nanoparticl
express
analyz
lung
tissu
inde
express
lung
infect
mice
receiv
sirnaload
capplga
nanoparticl
significantli
decreas
figur
b
consequ
also
viral
load
significantli
reduc
lung
day
figur
c
histopatholog
analysi
lung
tissu
reveal
less
structur
damag
less
infiltr
cell
mice
treat
sirna
compar
mice
treat
scrambl
sirnaload
capplga
nanoparticl
pb
histolog
score
significantli
decreas
almost
half
mice
receiv
sirna
treatment
figur
summari
result
illustr
promis
therapeut
approach
viral
infect
inflammatori
condit
lung
widespread
heterogen
includ
interstiti
lung
diseas
ild
chronic
obstruct
pulmonari
diseas
copd
asthma
character
airflow
limit
emphysema
fibrosi
bronchiti
despit
ongo
research
current
avail
therapi
mainli
inhal
aim
minim
symptom
aggrav
cur
inhal
open
airway
muscl
relax
interfer
activ
immun
system
unspecif
therefor
medic
treat
underli
inflamm
infect
might
improv
promis
treatment
strategi
use
inflammatori
model
base
h
lymphocyt
describ
import
effector
pulmonari
injuri
especi
ild
mani
diseas
includ
ild
copd
caus
excess
incorrect
activ
gene
abil
sirna
modul
gene
express
specif
molecular
level
offer
suitabl
approach
interfer
use
steril
model
lung
inflamm
analyz
potenc
local
modif
gene
express
sirna
sirna
direct
use
reduc
gene
express
inflam
lung
tissu
sirna
direct
influenza
viru
diminish
viral
replic
exert
function
sirna
must
deliv
target
tissu
demonstr
capplga
nanoparticl
success
use
deliveri
vehicl
lung
tissu
nanoparticl
protect
sirna
environ
use
decreas
gene
express
therebi
abrog
inflammatori
respons
lung
calcium
phosphat
previous
describ
safe
biocompat
biomed
carrier
due
natur
occurr
mammalian
hard
tissu
studi
use
cap
nanoparticl
encapsul
within
plga
safe
biodegrad
polym
use
pharmaceut
deliveri
vehicl
deliv
sirna
safe
target
cell
pei
differ
polym
appli
surfac
increas
cellular
uptak
endosom
escap
alongsid
increas
uptak
effici
pei
report
induc
inflammatori
respons
lung
howev
studi
inflammatori
effect
detect
might
due
highest
uptak
rate
macrophag
studi
studi
beyerl
colleagu
demonstr
pei
mainli
affect
alveolar
epitheli
cell
report
highlight
drug
deliveri
alveolar
macrophag
shown
effici
particl
low
micromet
rang
smaller
particl
suggest
toxic
effect
effect
might
due
distribut
nanoparticl
beyond
lung
blood
brain
howev
particl
nanoscal
behav
properti
depend
composit
public
notic
minim
transloc
nanoparticl
appli
lung
furthermor
compar
larger
particl
particl
nanoscal
target
varieti
cell
macrophag
result
increas
uptak
deliveri
activ
compound
previou
public
shown
composit
nanoparticl
highli
effici
achiev
increas
abil
gene
silenc
per
nanoparticl
well
effici
uptak
downregul
target
gene
mucos
surfac
patient
suffer
acut
chronic
lung
disord
increas
level
sever
chemokin
cytokin
sputum
sampl
blood
fluid
obtain
bal
model
regul
express
achiev
decreas
inflamm
lung
found
elev
lung
biopsi
patient
suffer
copd
wang
colleagu
demonstr
import
lung
relat
diseas
overexpress
mice
develop
pulmonari
emphysema
respons
secret
sever
cell
type
function
chemoattract
natur
killer
cell
macrophag
elev
blood
sputum
sampl
copd
patient
increas
level
found
correl
diseas
sever
similar
function
chemoattract
elev
sputum
sampl
patient
inflammatori
lung
condit
studi
regard
function
receptor
hardli
exist
howev
murin
antagonist
success
appli
reduc
influenza
viru
induc
lung
patholog
treatment
capplga
nanoparticl
load
sirna
three
target
gene
led
decreas
level
gene
express
h
model
lung
inflamm
thu
indirectli
shown
success
deliveri
sirna
releas
cytoplasm
cell
lung
nasal
instil
knockdown
three
mrna
suffici
decreas
protein
level
target
gene
importantli
restrict
pulmonari
inflamm
far
biolog
agent
proven
success
clinic
trial
inflammatori
condit
lung
one
reason
might
differ
phenotyp
vari
symptom
patient
furthermor
inflammatori
respons
like
driven
one
mediat
may
attribut
sever
dysregul
gene
sirnaload
capplga
nanoparticl
turn
promis
approach
easili
adapt
individu
patient
target
sever
overexpress
gene
interest
field
applic
sirnaload
capplga
nanoparticl
applic
lung
infect
virus
flu
caus
influenza
viru
rare
danger
due
effect
immun
sever
viral
infect
exist
potent
vaccin
avail
therapeut
rather
prophylact
approach
viral
infect
might
knockdown
viral
gene
express
proofofprincipl
experi
use
sirnaload
cap
plga
nanoparticl
direct
influenza
viru
demonstr
reduc
viral
load
patholog
knowledg
first
studi
use
sirna
therapeut
treatment
appli
nanoparticl
local
lung
previou
studi
exhibit
benefici
effect
intraven
prophylact
treatment
sirna
influenza
viral
infect
summari
abl
use
sirnaload
capplga
nanoparticl
cover
pei
direct
achiev
specif
knockdown
target
gene
express
vivo
rna
interfer
multipl
nasal
instil
abl
diminish
pulmonari
inflamm
caus
h
cell
addit
demonstr
benefici
effect
rna
interfer
viral
gene
therapeut
treatment
summari
data
provid
promis
approach
specif
deliveri
sirna
lung
treatment
pulmonari
inflamm
